publication . Other literature type . Article . 2010

Report of the task force on designing clinical trials in early (predementia) AD

Eric Salmon; Howard Feldman;
Open Access
  • Published: 22 Dec 2010
  • Publisher: Ovid Technologies (Wolters Kluwer Health)
Background: A large number of promising candidate disease-modifying treatments for Alzheimer disease (AD) continue to advance into phase II and phase III testing. However, most completed trials have failed to demonstrate efficacy, and there is growing concern that methodologic difficulties may contribute to these clinical trial failures. The optimal time to intervene with such treatments is probably in the years prior to the onset of dementia, before the neuropathology has progressed to the advanced stage corresponding to clinical dementia. Method: An international task force of individuals from academia, industry, nonprofit foundations, and regulatory agencies ...
free text keywords: Clinical Neurology, Views and Reviews
Powered by OpenAIRE Research Graph
Any information missing or wrong?Report an Issue